Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2022-11-26 Director's Dealing
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-11-26 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-11-22 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Collegium Pharmaceutical, Inc. It reports the issuance of a press release announcing quarterly financial results and an earnings presentation for the quarter ended September 30, 2022. The document itself does not contain the financial results or detailed financial statements but rather attaches the press release and presentation as exhibits. The length is 3773 characters, which is relatively short and consistent with a report publication or regulatory filing rather than a full financial report. The document explicitly states that the press release and presentation are being furnished, not filed, under Item 2.02 and Item 7.01 respectively. This indicates the document is primarily an announcement of earnings results and presentation, not the earnings release itself. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing the release of financial results and presentation but does not contain the substantive financial data itself. Confidence is high due to clear SEC form type, explicit references, and document length.
2022-11-03 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-10-06 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-09-16 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.